1 / 15

Agenda

Agenda. What? Who? Why? How?. Program Overview: Rapid Vector Diagnostics for Military Deployments. . COL Russell Coleman, CPT Elizabeth Wanja and Professor Michael Faulde.

zinna
Download Presentation

Agenda

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Agenda • What? • Who? • Why? • How?

  2. Program Overview: Rapid Vector Diagnostics for Military Deployments. COL Russell Coleman, CPT Elizabeth Wanja and Professor Michael Faulde The opinions or assertions contained herein are the private views of the author, and are not to be construed as official, or as reflecting true views of the Department of the Army or the Department of Defense.

  3. Why Vector Diagnostics? • Medical mission is preserve the fighting force; • Threat is not the arthropods but the diseases they carry; • Knowing what diseases are present and where allows for targeted vector control;

  4. CONOPS • Part of integrated effort (collect, ID arthropod, pathogen detection, control) • Two-tiered System • Hand-held assays used by BCT PM staff or PVNTMED Det; • Molecular assays used by laboratory (AML, FDPMU, AF BAT, CSH, CHPPM…) • Negative results minimal value, positive results tremendous value • Allow for targeted control efforts; • Get action from non-medical types;

  5. Product Development Process User Needs Technology Opportunities & Resources MDD A B C Program Initiation DoD Research ICD Technology Development Engineering & Manufacturing Development Production & Deployment Operations & Support Materiel Solution Analysis ICD CDD CPD Procurement OMA 6.1 6.2 6.5 6.3 6.4 6.7 CAPABILITY DEVELOPMENT DOCUMENT (CDD)  ARTHROPOD VECTOR RAPID DIAGNOSTIC DEVICES (AV-RDD)  Increment: I  ACAT: III  Validation & Approval Authority: HQDA Milestone Decision Authority: CG, USAMRMC  Draft Version 1.8  23 December 2009

  6. Fielding Plan

  7. Phased in Fielding

  8. AV-RDD Attributes

  9. Current Status of AV-RDD • Malaria (falciparum and vivax): Fielded • North American Arboviruses (WN, WEE, SLE, EEE): Fielded • Rift Valley fever virus (Ph II SBIR): Field studies • Dengue (Ph II SBIR): Lab studies • Leishmaniasis (Ph II SBIR): Lab studies • Sand fly fever virus (Ph II SBIR): Lab studies • Tick-borne pathogen multiplex (CCHF/TBE/Rickettsia, Ph 1 SBIR): Lab studies

  10. Current Status of AV-RDD • All previous and current efforts are Immuno-chromatographic wicking assays developed by Dr. Kirti Dave, currently VecTOR Test Systems; • Diagnostic technology rapidly changing and could be incorporated into this program.

  11. Use of AV-RDD during Deployments • Malaria VecTEST Assay widely used in Iraq and Afghanistan. • Iraq: Few anophelines, few assays run, no positives. In 2003/2004 negative data assisted in decision to remove requirement for mandatory malaria chemoprophylaxis; • Afghanistan: More anophelines, more assays run, a number of positives. Data helped shaped control programs; • Comments/Thoughts???

  12. ?

More Related